Results 21 to 30 of about 526 (152)

A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness. [PDF]

Psychopharmacol Bull
Purpose of Review This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this ...
Fuller MC, Carlson S, Pysick H, Berry V, Tondryk A, Swartz H, Cornett EM, Kaye AM, Viswanath O, Urits I, Kaye AD.   +10 more
europepmc   +3 more sources

Solriamfetol enhances alertness and cognitive performance in mice

Abstract Solriamfetol [(R)-2-amino-3-phenylpropylcarbamate hydrochloride], a phenylalanine derivative initially developed as potential antidepressant, was shown by our group in 2009 to have potent, dose-dependent wake-promoting activity in mice.
Haddar M, Tzanoulinou S, Chen LY, Tafti M, Vassalli A.   +4 more
europepmc   +2 more sources

Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA [PDF]

Chest, 2021
BACKGROUND: Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, is approved in the United States to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with OSA (37.5-150 mg/d).
Paula K. Schweitzer, Geert Mayer, Russell Rosenberg, Atul Malhotra, Gary K. Zammit, Mark Gotfried, Patricia Chandler, Michelle Baladi, Kingman P. Strohl   +8 more
openaire   +3 more sources

481 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with narcolepsy and solriamfetol prescriber rationale [PDF]

Sleep, 2021
Abstract Introduction Pharmacotherapy for excessive daytime sleepiness (EDS) associated with narcolepsy is diverse, with factors such as efficacy, side effects, and tolerance influencing treatment decisions.
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +2 more sources

Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. [PDF]

Arthritis Rheumatol
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Hlavaty A, Dari L, Cracowski JL, Roustit M, Khouri C.   +4 more
europepmc   +2 more sources

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol [PDF]

SLEEP Advances, 2021
Abstract Introduction Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnoea (OSA) (37.5–150 mg/day).
Thorpy, M, Hyman, D, Parks, G, Chen, A, Foley, C, Ito, D, Singh, H   +6 more
openaire   +1 more source

Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions. [PDF]

Neurol Ther, 2023
IntroductionExcessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) can impair vigilance/attention. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved to treat EDS associated with narcolepsy (75-
Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, Donjacour CEHM, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, Lammers GJ.   +15 more
europepmc   +5 more sources

Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea. [PDF]

Chronic Dis Transl Med
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Preshy A, Fernandez CJ, Nedai MH, Pappachan JM.   +3 more
europepmc   +2 more sources

Solriamfetol for the Use of Narcolepsy: A Systematic Review

Cureus, 2022
Narcolepsy is a chronic and disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. Historically, some medications have demonstrated efficacy in managing EDS and cataplexy symptoms. However, some patients cannot tolerate them, become refractory, or may use concomitant medications that preclude the use due to ...
Iturburu, Alisson, Pallares Vela, Elisa, Cruz, Claudio, Yepez, Mario, Ortiz, Juan Fernando, Krishna, Krithika, Peña, Gabriela, Cordova, Steven, Khurana, Mahika, Bandarupalli, Pranathi   +9 more
openaire   +2 more sources

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol

Pharmacology Research & Perspectives, 2021
Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea.
Stéphane Krief, Isabelle Berrebi‐Bertrand, Isabelle Nagmar, Martin Giret, Simon Belliard, David Perrin, Marilyne Uguen, Philippe Robert, Jeanne‐Marie Lecomte, Jean‐Charles Schwartz, Olivier Finance, Xavier Ligneau   +11 more
doaj   +1 more source